Wedbush views Karyopharm ‘s PDUFA date extension as a positive

Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled “FDA Extends PDUFA by Three Months,” he said he is inclined to view the extension as a positive for the company “given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely.”
https://thefly.com/landingPageNews.php?id=2879891